Cellebrite DI (CLBT) Change in Accured Expenses (2020 - 2025)

Cellebrite DI's Change in Accured Expenses history runs 6 years deep, the most recent figure standing at $6.8 million for Q4 2025.

• On a quarterly basis, Change in Accured Expenses fell 41.9% year-over-year to $6.8 million in Q4 2025; TTM through Dec 2025 was $4.2 million, a 75.84% decrease from a year earlier, with the FY2025 full-year figure at $4.2 million, down 75.84% from the prior year.
• Change in Accured Expenses rose to $6.8 million in Q4 2025 per CLBT's latest filing, from -$8.0 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $17.6 million in Q2 2025 and bottomed at -$12.2 million in Q1 2025.
• The 5-year median for Change in Accured Expenses is $2.4 million (2021), against an average of $945850.0.
• Across the five-year window, Change in Accured Expenses jumped 809.28% in 2024 and slumped 187.46% in 2025, its largest moves.
• Year by year, Change in Accured Expenses stood at $2.5 million in 2021, then plunged by 181.68% to -$2.1 million in 2022, then surged by 370.44% to $5.6 million in 2023, then surged by 110.41% to $11.7 million in 2024, then plunged by 41.9% to $6.8 million in 2025.
• Per Business Quant, the three latest CLBT Change in Accured Expenses figures stand at $6.8 million (Q4 2025), -$8.0 million (Q3 2025), and $17.6 million (Q2 2025).